Drug Approval | October 04, 2021
Lilly to transfer rights of two diabetes drugs to Cipla in India
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
The kit preserves viral nucleic acids in a non-hazardous stabilization solution that inactivates common respiratory viruses for safer sample collection
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
The NanoDrop Eight simultaneously evaluates eight samples in 20 seconds or less and the instrument can also measure high-concentration samples of up to 200 absorbance units without dilution
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Barbara Engelhardt moves her computational and statistics lab to Gladstone
The order strengthens the company’s position in the East African market
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
Subscribe To Our Newsletter & Stay Updated
